Skip to main content

MBL and MASP‐2 concentrations in serum and MBL2 promoter polymorphisms are associated to schizophrenia

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Foldager L, Steffensen R, Thiel S, Als TD, Nielsen HJ, Nordentoft M, Mortensen PB, Mors O, Jensenius JC. MBL and MASP‐2 concentrations in serum and MBL2 promoter polymorphisms are associated to schizophrenia.

Objective: Causative relations between infections and psychosis, especially schizophrenia, have been speculated for more than a century, suggesting a hypothesis of association between schizophrenia and hereditary immune defects. Mannan‐binding lectin (MBL) is a pattern‐recognition molecule of the innate immune defence. MBL deficiency is the most common hereditary defect in the immune system and may predispose to infection and autoimmunity. Mannan‐binding lectin serine protease‐2 (MASP‐2) is an MBL‐associated serine protease mediating complement activation upon binding of MBL/MASP to microorganisms. The objective was to investigate if schizophrenia is associated with serum concentrations of MBL and MASP‐2 or with genetic variants of the genes MBL2 and MASP2 encoding these proteins.

Methods: The sample consisted of 100 patients with schizophrenia and 350 controls. Concentrations of MBL and MASP‐2 in serum were measured and seven single nucleotide polymorphisms known to influence these concentrations were genotyped.

Results: Significant association of disease with genetic markers was found in MBL2 but not in MASP2. Significant difference in MBL serum concentration was found between patients and controls when adjusting for MBL2 haplotypes. For concentrations of MASP‐2, a significant interaction effect between a MASP2 variant and disease was found. Interestingly, MASP‐2 levels also depended significantly on variants in MBL2 exon 1.

Conclusion: This study supports previous studies showing increased complement activity in patients with schizophrenia, indicates aetiological heterogeneity among patients and underlines that multilocus genotypes have to be considered when investigating effects on MBL level. It appears that inclusion of additional components from the system of complement activation is warranted.

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1601-5215.2011.00618.x

Affiliations: 1: Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark 2: Institute of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark 3: Department of Surgical Gastroenterology 435, Hvidovre University Hospital, Hvidovre, Denmark 4: Psychiatric Centre Copenhagen, University of Copenhagen, Copenhagen, Denmark 5: National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark 6: Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark

Publication date: 2012-08-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more